The Bristol start-up secured £150k from British Design Fund within a £500k raise to accelerate its AI-driven aquatic rehabilitation platform.
"Pain and joint conditions, collectively known as musculoskeletal (MSK) conditions, affect 20m people in the UK and 1.7bn people globally. Many of these disorders can be effectively treated and managed through water-based therapeutic interventions. However, until now, we have been unable to measure movement in water to assess the power, speed or range of movement with any accuracy. We’re delighted to say Good Boost has cracked that engineering challenge. On the sports side, injuries account for 60% of player absences, with an average of 2.5 injuries per player, per season. Our technology can help ensure that athletes’ recovery, rehab and conditioning is tailored to individual needs, providing analysis and feedback as part of an athlete’s aquatic recovery programme."
The seed round was led by Heal Capital to support platform development and expand community-based care pathways.
"For a long time, healthcare was rooted in the community. This brought so many benefits to both patients and practitioners, but in recent decades it’s become completely cost-ineffective to deliver it. Meanwhile, secondary care is becoming increasingly bottlenecked, with waiting lists at an all-time high and discharge delays keeping patients in hospital longer than they need. Our mission with Heim Health is to build the digital infrastructure needed to change this; revitalising community-based care and moving more healthcare from the hospital into the home through scalable modes of delivery."
The London-based SaaS and fintech platform raised the funds from General Catalyst, Morpheus Ventures and Repeat to further develop its technology stack.
"Goodstack enables its customers to serve all stakeholders—employees, customers, and communities—by supporting nonprofits and charitable giving. The validation and trust that partners like LinkedIn and Canva have in Goodstack is a powerful testament to the company’s value, and combined with strong leadership, positions Goodstack well for continued success."
The Series A financing was led by Par Equity to support international expansion and product development.
"Securing this investment allows us to scale our impact across healthcare and life sciences, with a focus on easing the burden of paediatric clinical trials. While legislation like RACE, SPCs, and the ODA has increased study numbers, specialist paediatric knowledge is still lacking in the industry. This has led to lower recruitment, adherence and trial completion rates compared to adult research. Little Journey is uniquely positioned to fill this expertise gap and tackle these challenges to advance global paediatric medicine. With the backing of Par Equity, Mercia Ventures, Octopus Ventures, and our wider investor network, we’re redefining how paediatric clinical trials are run and putting families at the heart of them."
